Table of Content

08 May 2016, Volume 43 Issue 5 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Effect of P2X7R agonist BzATP on cell growth and apoptosis in non-small cell lung cancer A549 cells Zeng Kanghua, Ru Qin, Xiong Qi, Ai Yongxun 2016, 43 (5):  321-325.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.001 Abstract ( 434 )   PDF (1260KB) ( 1389 )   Save ObjectiveTo investigate the expression of P2X7 receptor (P2X7R) and the effect of P2X7R agonist 2′3′O(4benzoylbenzoyl) ethane adenosine triphosphate three amine salt (BzATP) on cell growth and apoptosis in nonsmall cell lung cancer A549 cells, and to explore the related mechanism. MethodsThe expression of P2X7R in A549 cells was detected by immunofluorescence. Cells were treated with different concentrations (150, 300, 600 μmol/L) of BzATP. Cells untreated with BzATP were used as control group. 3(4,5dimethyl2thiazoly)2,5diphenyl2Htetrazolium bromide (MTT) assay and Hoest33342 staining were respectively used to detect cell viability and apoptosis. Enzymelinked immunosorbent assay (ELISA) was uesd to detect the concentration of tumor necrosis factorα (TNFα) of cell culture supernatants. The expressions of nuclear factorκB (NFκB) p65, inhibitor of α of NFκB (IκBα) and the phosphorylation of inhibitor of α of NFκB (phosphoIκBα) were detected by Western blotting. ResultsP2X7R was expressed on the cell membrane of A549 cells. Survival rate of A549 cell was significantly decreased with the concentrations of BzATP at 300 and 600 μmol/L ［(67.87±8.98)%, (44.73±6.92)%］, compared with the control group (98.60±1.44)%, the differences were statistically significant (t=4.481, P=0.027; t=3.920, P=0.038). BzATP promoted apoptosis, and increased the concentration of TNFα of supernatant at 300 and 600 μmol/L ［(57.35±6.41)pg/ml, (78.63±11.33)pg/ml］, compared with the control group (42.56±0.37)pg/ml, the differences were statistically significant (t=6.410, P=0.035; t=11.330, P=0.005). In addation, the expressions of NFκB p65 and IκBα were respectively downregulated and upregulated by BzATP, while the expression of phosphoIκBα was not significantly altered. ConclusionP2X7R is expressed on A549 cell membrane. BzATP can inhibit cell proliferation and induce the apoptosis of A549 cells, and the mechanism of action may be related to promoting the release of TNFα and inhibition of NFκB pathway. References | Related Articles | Metrics

Investigation of the curative effect of chemotherapy combined with DC-CIK cell immunotherapy in metastatic breast carcinoma Gao Haiyan, Zhu Yulan, Sun Li 2016, 43 (5):  326-329.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.002 Abstract ( 407 )   PDF (728KB) ( 1086 )   Save ObjectiveTo compare the efficacy and adverse reactions of TA regimen (docetaxel + epirubicin) and immunization therapy of TA regimen combined with dendritic cell (DC)cytokine induced killer cell (CIK) in treating the patients with metastatic breast cancer (MBC). MethodsClinical data of 43 patients with MBC received treatment in our hospital from January 2011 to January 2013 were retrospectively analyzed. Patients included were divided into two groups according to the treatment, simple treatment group (TA regimen, control group, 22 cases) and combined treatment group (TA regimen + DCCIK cell, observation group, 21 cases). The curative effect, improvement situation of clinical symptoms, adverse reactions and changes of T cell immune phenotype in peripheral blood of patients before and after treatment in the two groups were compared. ResultsThe total efficiency of treatment in observation group (85.7%) was higher than that in control group (63.6%), and the difference was statistical significant (χ2=4.949, P=0.026). Among the incidences of all kinds of adverse reaction appeared during the treatment in two groups, the white blood cells count decreased was the highest in observation group (76.2%) and in control group (59.1%), the difference had no statistical significance (χ2=0.858, P=0.36). After treatment, the rates of fatigue, loss of appetite, insomnia and night sweats of patients in observation group were lower than those in control group (23.8% vs. 54.5%, χ2=4.246, P=0.04; 19.0% vs. 54.5%, χ2=5.795, P=0.02; 19.0% vs. 50.0%, χ2=4.532, P=0.03). The CD3+ (60.4±12.3 vs. 47.4±12.8, t=3.393, P<0.01), CD3+/CD4+ (41.7±9.6 vs. 28.1±10.5, t=5.442, P<0.01), CD4+/CD8+ (1.5±0.2 vs. 1.0±0.2, t=8.195, P<0.01), NK cells (27.3±5.9 vs. 15.3±6.1, t=6.643, P<0.01), NK T cells (14.7±1.4 vs. 6.0±1.2, t=11.020, P<0.01) after treatment in observation group were obviously higher than those in control group. ConclusionComparing with the pure TA scheme, the curative effect of immunization therapy of TA regimen combined with DCCIK cell in treating the patients with MBC is better. It significantly improves the immune functions of patients with MBC, and does not increase adverse reaction. References | Related Articles | Metrics

Clinical observation of oxaliplatin combined with S-1 on the patients with advanced breast cancer Liu Jun, Xiao Yang, Ma Yihui, Guo Jianxiong, Liu Yangchen, Huang Xiaohong, Zhang Rongxia 2016, 43 (5):  330-334.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.003 Abstract ( 498 )   PDF (733KB) ( 1358 )   Save ObjectiveTo evaluate the efficacy and toxicity of the combination of oxaliplatin and S1 in the treatment of patients with advanced breast cancer. MethodsA total of 72 patients with advanced breast cancer after the treatment failuer of anthracycline and taxane were treated with oxaliplatin and S1. The first day, they were given oxaliplatin, 135 mg/m2, with the 5% glucose injection 500 ml, the time of intravenous drip should be more than 2 hours. And the S1 was taken after breakfast and dinner, the dose was 4060 mg, and the time of duration was 2 weeks, then they had 7 days to rest. The cycle was 21 days. Every 2 cycles, we estimated the efficacy. Patients who were effective and stable kept that chemotherapy regimens, the maximum duration was 6 cycles. The efficacy and toxicities were evaluated after cycles of chemotherapy. ResultsTwo cases (2.8%) had complete response (CR), 26 cases (36.1%) had partial response (PR). The response rate (RR) was 38.9% and the disease control rate (DCR) was 69.4%. The median progress free survival (PFS) was 7.7 months and the median overall survival (OS) was 12.3 months. Subgroup analysis showed that the OS of patients who belong to stage Ⅳ, had two or more metastases or with failure treatment after being treated with anthracycline and taxane was notably shorter than the patients who belong to stage ⅢC, only one metastasis, with effective treatment after being treated with anthracycline and taxane, and the differences were statistically significant (10.5 months vs. 15.0 months, χ2=4.469, P=0.035; 9.3 months vs. 15.0 months, χ2=8.297, P=0.004; 10.0 months vs. 14.0 months, χ2=4.077, P=0.043). The main side effects were neutropenia (19.4%), nausea (8.3%) and nerve toxicity (2.8%), mainly 34 degree, and could be welltolerated. The others were diarrhea, impaired liver function, stomatitis, anemia and handfoot syndrome, mainly 12 degree. ConclusionOxaliplatin combined with S1 is effective and tolerable in treatment of patients with advanced breast cancer, the adverse reactions can be tolerated. References | Related Articles | Metrics

Effect of chemotherapy on the expression of CD8+CD28-T cells in peripheral blood of nonsmallcell lung cancer patients Liang Guanzhong, Wang Yanfeng, Han Fucai 2016, 43 (5):  335-339.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.004 Abstract ( 366 )   PDF (1573KB) ( 994 )   Save ObjectiveTo observe the expression of CD8＋CD28-T cells in the peripheral blood of nonsmallcell lung cancer (NSCLC) patients, and to investigate the effect of chemotherapy on CD8＋CD28-T cells expression and its clinical significance. MethodsFlow cytometry was used to evaluate the level of CD8＋CD28-T cells in peripheral blood of 70 untreated NSCLC patients and 60 healthy controls. The association between CD8＋CD28-T cells and the clinical features was analyzed. We also investigated the changes of CD8＋CD28-T cells in 30 NSCLC patients who received chemotherapy by GP (gemcitabine, cisplatin) and NP (navelbine, cisplatin). ResultsThe proportion of CD8＋CD28-T cells in lung cancer group was significantly higher than that in healthy group (59.003%±15.329% vs. 41.036%±15.435%, t=35.904, P=0.001). No correlation was found between  CD8＋CD28-T cells expression and the gender (F=1.374, P=0.697), pathological  pattern (F=0.779, P=0.509) and clinical stage (F=0.070, P=0.933). But CD8＋CD28-T cells expression was correlated with the age (F=15.038, P=0.001). The level of CD8＋CD28-T cells after NP chemotherapy was lower than that before chemotherapy (55.293%±14.637% vs. 58.793%±12.510%, t=2.017, P=0.044). And the level of CD8＋CD28-T cells after GP chemotherapy was lower than that before chemotherapy (54.127%±13.924% vs. 60.700%±16.401%, t=3.007, P=0.009). ConclusionCD8＋CD28-T cells express highly in NSCLC patients peripheral blood. Chemotherapy downregulates CD8＋CD28-T cells expression, which provides a new reference for combination with chemotherapy and immunotherapy in NSCLC patients. References | Related Articles | Metrics

Detection of ALK gene rearrangement in nonsmall cell lung cancer Zhao Xiaolei, Li Sanhua, Liu Lingling, Liang Yongbo, Niu Yinyin, Zhai Jinyu, Xu Yuyin, Qiu Jinkui, Qi Hua 2016, 43 (5):  340-342.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.005 Abstract ( 615 )   PDF (931KB) ( 1307 )   Save ObjectiveTo detect  anaplastic lymphoma kinase (ALK) gene rearrangement in nonsmall cell lung cancer (NSCLC) by fluorescent in situ hybridization (FISH). MethodsAccording to ALK gene rearrangement manners, dualcolor (Red/Green) fluorescence probes were designed and labeled. Specificity and sensitivity were evaluated in peripheral blood metaphase of lymphocyte cells. Test performances were evaluated in NSCLC paraffin tissue samples by FISH and immunohistochemistry. ResultsBoth specificity and sensitivity reached 100% in EpsteinBarr virus (EBV) transformed human lymphocyte cells. The established FISH method detected one ALK gene rearrangement case among two NSCLC samples successfully. The results of FISH were consistent with the results of immunohistochemistry. ConclusionThe dualcolor probe designed in this study can be used for ALK gene rearrangement testing in NSCLC. References | Related Articles | Metrics

Expression of RRM1 in gastric adenocarcinoma and its relationship with clinical pathological characteristics Lin Chenshi, Yang Jiyuan 2016, 43 (5):  343-345.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.006 Abstract ( 571 )   PDF (942KB) ( 1284 )   Save ObjectiveTo investigate the expression of human ribonucleotide reductase large subunit M1 (RRM1) in the patients with gastric adenocarcinoma and its clinical significance. MethodsThe expressions of RRM1 were detected in 88 cases of gastric adenocarcinoma and 20 cases of normal gastric tissues by immunohistochemical method. The correlations between the expression of RRM1 and clinicopathological characteristics were analyzed. ResultsThe positive expression rate of RRM1 in gastric adenocarcinoma was 83.0% (73/88). And RRM1 was negative in the entire normal gastric tissues. The positive expression of RRM1 was not associated with patient′s age (χ2=0.352, P=0.553), gender (χ2=0.493, P=0.482), depth of tumor infiltration depth (χ2=0.007, P=0.933), lymph nodes metastasis (χ2=0.121, P=0.728) and distant metastasis (P=0.415). But it was related to the degree of tumor differentiation (χ2=7.740, P=0.021) and clinical stage (χ2=5.733, P=0.017).  ConclusionThe expression of RRM1 is positive expression in most gastric adenocarcinoma, and is associated with the degree of tumor differentiation and clinical stage. It is of great significance to detect the expression of RRM1 in gastric adenocarcinoma for confirming the diagnosis and judging malignant degree of the tumor. It also may have potential value in choosing the best therapeutic scheme and estimating prognosis. References | Related Articles | Metrics

Expressions of UHRF1, P53 and their clinical significances in colon carcinoma Ai Xiaoqing, Jia Xihua, Wang Xiaobo, Zheng Shujun, Zhao Xia, Zhang Bingxin 2016, 43 (5):  346-349.  doi: 10.3760/cma.j.issn.1673422X.2016.05.007 Abstract ( 452 )   PDF (908KB) ( 969 )   Save ObjectiveTo investigate the expression levels and clinical significances of ubiquitinlike with PHD and ring finger domains 1 (UHRF1) and P53 in colon carcinoma. MethodsThe expressions of UHRF1 and P53 in 70 colon cancer tissues and 30 normal colon ones were detected by means of immunohistochemistry to analyze the correlation of these two proteins in the occurrence and development of colon carcinoma, and the relationship between their expressions and clinicopathological factors as well as prognosis was discussed. ResultsThe expression levels of UHRF1 and P53 in cancer tissues were significantly higher than those of canceradjacent tissues (87.1% vs. 56.7%, χ2=11.366, P=0.001; 64.3% vs. 6.7%, χ2=27.988, P=0.000) and showed a positive correlation between the two proteins (r=0.248, P=0.038). Both UHRF1 and P53 were associated with TNM stages (χ2=4.426, P=0.049; χ2=6.000, P=0.016) and the depth of invasion (χ2=12.553, P=0.002; χ2=4.904, P=0.036). However, they were irrelevant with the age (χ2=0.473, P=0.494; χ2=0.090, P=0.799) and gender (χ2=2.297, P=0.166; χ2=0.512, P=0.617) of patients, as well as the size (χ2=0.638, P=0.481; χ2=2.392, P=0.215) and histological grading of tumors (χ2=2.088, P=0.352; χ2=0.303, P=0.859). KaplanMeier analysis showed that the median survival time of patients with UHRF1, P53 positive expression was 21.83 months that was lower than patients with UHRF1 positive expression of 24.49 months (Z=－0.624, P=0.533). Both former of which was distinctly lower than that of negative ones of 37.33 months (Z=－2.856, P=0.004; Z=－2.694, P=0.007). ConclusionBoth UHRF1 and P53 are highly expressed in colon cancer tissues, which imply that UHRF1 and P53 may be strongly related with colon cancer development and can be a predictor for colon cancer prognosis. References | Related Articles | Metrics

Expressions and clinical significances of Runx3 and CHD5 in colorectal cancer Ma Dong, Sun Xuejun 2016, 43 (5):  350-355.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.008 Abstract ( 363 )   PDF (1151KB) ( 907 )   Save ObjectiveTo investigate the expressions and clinical significances of Runtdomainrelated 3 (Runx3) and chromodomain helicase DNAbinding protein 5 (CHD5) in colorectal cancer. MethodsNinetysix colorectal cancer tissue samples and matched adjacent normal tissues and 72 colorectal adenoma tissues were collected. Realtime quantitative polymerase chain reaction (qRTPCR) and Western blotting were used to detect the mRNA and protein expression of Runx3 and CHD5. The associations of Runx3 and CHD5 expression with clinical pathological characteristics, diagnostic value and prognosis relationship of patients were further analyzed. ResultsRunx3 and CHD5 relative expressions of mRNA and protein were 0.35±0.00, 0.28±0.02 and 0.26±0.02, 0.31±0.01, which were significantly lower than those in the matched adjacent tissues 0.95±0.02, 0.92±0.02 and 0.89±0.03, 0.93±0.02 (t=2.36, P＜0.05; t=1.25, P＜0.05; t=1.37, P＜0.05; t=1.13, P＜0.05) and colorectal adenoma tissues 0.89±0.02, 0.90±0.02 and 0.85±0.02, 0.87±0.04 (t=2.27, P＜0.05; t=2.16, P＜0.05; t=1.25, P＜0.05; t=2.65, P＜0.05). Runx3 and CHD5 expressions differed significantly between tumors with different TNM stages (χ2=4.65, P=0.031; χ2=7.89, P=0.005), depths of tumor invasion (χ2=4.17, P=0.041; χ2=4.86, P=0.028), lymph node statuses (χ2=4.20, P=0.040; χ2=7.02, P=0.008), or histological differentiation (χ2=7.31, P=0.036; χ2=9.54, P=0.023). Linear correlation analysis showed that the expressions of the two genes were positively correlated (r=0.572, P=0.001). Receiver operating characteristic (ROC) curve showed that Runx3 and CHD5 had diagnostic value (AUC were 0.712, 0.745; sensitivity and specificity were 45.9%, 52.5% and 83.6%, 81.4% respectively). Runx3 and CHD5 both low expression group compared with the other patient groups in overall survival time (χ2=8.156， P＜0.05) and progressionfree survival (χ2=6.325, P<0.05) had statistically significant differences. ConclusionRunx3 and CHD5 are low expressed in colorectal cancer and may prove useful as biomarkers for diagnosis target and prognostic indication in patients with colorectal cancer. References | Related Articles | Metrics

Molecular mechanism of tumor associated hypercoagulability Zhang Xue, Jiang Da, Li Ying 2016, 43 (5):  356-359.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.009 Abstract ( 448 )   PDF (725KB) ( 1430 )   Save The process of tumorigenesis, local invasion and distant metastasis will produce a series of molecular changes, these genetic mutation or abnormal expression of molecules play a promoting role in hypercoagulation. At the same time, hypercoagulation also increases the risk of tumor progression. It is important to understand their specific processes and the molecular role, and it can provide theoretical basis for better management of patients, and has significance for developing more effective and security new anticlotting drugs. References | Related Articles | Metrics

Advances in research of rhendostatin in the treatment of cancer Xie Wenyao, Jiang Da, Yang Zhiyong, Dong Qian 2016, 43 (5):  360-363.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.010 Abstract ( 455 )   PDF (785KB) ( 1260 )   Save Recombinant human endostatin (Endostar) is a broad spectrum molecular targeted drug on antiangiogenesis that the main evidencebased data is combined chemotherapy treatment of advanced nonsmall cell lung cancer (NSCLC). In recent years, the researches of recombinant human endostatin used in the treatment of various malignant tumors are on the increase and achieve good effect. In addition, the researches about combined treatment methods, routes of administration, methods of medication are carried out gradually, which will be conducive to the reasonable application in clinical. References | Related Articles | Metrics

Reversing methods of tumor multidrug resistance Chen Ying, Zhang Xingping 2016, 43 (5):  364-367.  doi: 10.3760/cma.j.issn.1673422X.2016.05.011 Abstract ( 467 )   PDF (728KB) ( 1438 )   Save Chemotherapy is one of the main treatment methods in malignant tumor. Tumor multidrug resistance (MDR) is one of the important reasons for the failure of chemotherapy. It makes some progress in reversing tumor MDR, such as chemical drug, traditional Chinese medicine, immunotherapy, gene therapy, nanoparticles drug system and so on. But it takes more effort to develop medicine of less adverse reactions, better pharmacodynamic and application to clinic widely. References | Related Articles | Metrics

Detection technologies of circulating tumor cells Li Shuling, Liu Jing, Wei Wenqing 2016, 43 (5):  368-371.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.012 Abstract ( 476 )   PDF (720KB) ( 1540 )   Save Circulating tumor cells (CTCs) detections have unique advantages in the realtime personalized medicine of patients with tumors. The rarity and heterogeneity of CTCs in peripheral blood pose great technical challenge for CTCs researches. Most of technologies for detecting CTCs have been developed to enrich CTCs by virtue of physical properties or specific biological features of the cells at first, then genotype or phenotype analysis are performed to count or characterize CTCs. Advances in molecular analysis of single cells enable CTCs detections to provide more accurate and comprehensive information. Biological processes during CTCs invasion and metastasis such as epithelialmesenchymal transition and clustering should to be considered seriously to promote the clinical applications of CTCs detection. References | Related Articles | Metrics

Nasopharyngeal carcinoma and tumor escape Li Zhoulei, Ren Yanxin, Li Xiaojiang 2016, 43 (5):  372-375.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.013 Abstract ( 535 )   PDF (724KB) ( 1181 )   Save Tumor immune evasion is a hallmark of cancer. There are many mechanisms of tumor escape, which mainly include the direct immune escape of tumor and tumor microenvironment mediated immune escape. Recent studies have shown that the development of nasopharyngeal carcinoma and its tumor cells are closely related to the immune escape. The direct immune escape of tumor which is associated with nasopharyngeal carcinoma including the expression decreased or absent of the major histocompatibility complexⅠ on the surface of tumor cell, the lack of costimulatory molecules of tumor and the Fas/FasL system mediated immune escape. And the tumor microenvironment mediated immune escape which is associated with nasopharyngeal carcinoma including the immunosuppressive molecule and the immunosuppressive cells of tumor. Researches on the mechanisms of tumor immune evasion can provide new target for treatment and prevention of nasopharyngeal carcinoma. References | Related Articles | Metrics

Adjuvant radiotherapy in breast cancer patients after radical mastectomy or modified radical mastectomy Sun Ying, Zhang Haibo, Yan Ying 2016, 43 (5):  376-378.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.014 Abstract ( 450 )   PDF (722KB) ( 1733 )   Save In recent years, the influencing factors of prognosis and effect after radiotherapy in breast cancer patients with radical mastectomy or modified radical mastectomy have gradually become a hot research, and it is closely related with the stages, subtypes, hormone levels and the body mass index (BMI). Otherwise, from three dimensional conformal radiation therapy to helical tomotherapy, the development of radiation technology has a breakthrough progress and makes the treatment of diseases more accurate and rational. References | Related Articles | Metrics

Mechanism of curcumin resisting esophageal cancer Tian Ruonan,Sun Jianjing, Zhang Linxi 2016, 43 (5):  379-381.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.015 Abstract ( 325 )   PDF (717KB) ( 1272 )   Save Curcumin can suppress the proliferation of esophageal cancer cells by inducing cell cycle arrest and blocking Notch signaling pathway, and can inhibit the invasiveness of esophageal cancer cells by inhibiting the nuclear factorκB (NFκB) signaling pathway and suppressing the formation of tumor blood vessels and inhibiting matrix metalloproteinase (MMP). Curcumin can also regulate apoptosis of esophageal cancer cells by changing the expression and localization of nucleophosmin. References | Related Articles | Metrics

Research progress of CTHRC1 in gastrointestinal cancers Wang Yan, Wang Lu, Feng Jiangzhou, Li Deng 2016, 43 (5):  382-384.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.016 Abstract ( 560 )   PDF (717KB) ( 1268 )   Save Collagen triple helix repeat containing 1 (CTHRC1) can repair the injured vessel by limiting the deposition of collagen and promoting cell migration. CTHRC1 is mainly regulated by WntPCP signaling pathway， transforming growth factor (TGF)bone morphogenetic protein (BMP) signaling pathway and extracellular signalregulated kinase (ERK)matrix metalloproteinase 9 (MMP9) signaling pathway. Recent studies have identified that CTHRC1 is aberrantly expressed in gastrointestinal cancers and associated with the occurring and development of cancers. References | Related Articles | Metrics

Signaling pathways of epithelialmesenchymal transition in colon cancer Li Xiaoqing, Li Yuanfei 2016, 43 (5):  385-386.  doi: 10.3760/cma.j.issn.1673422X.2016.05.017 Abstract ( 356 )   PDF (713KB) ( 1438 )   Save Epithelialmesenchymal transition (EMT) plays a critical role in the carcinogenesis of colon cancer, and promotes the tumor invasion and metastasis. Studies have shown several signals are involved including transforming growth factorβ (TGFβ), Wnt/βcatein, Notch, nuclear factorκB (NFκB) and PI3K/Akt signal pathway. It is important to elucidate EMTrelated signal pathway thereby providing new insights into possible therapeutic interventions of colon cancer. References | Related Articles | Metrics

Treatment strategy for advanced colorectal cancer Liu Debao, Xu Zhongfa, Fan Kaixi 2016, 43 (5):  387-390.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.018 Abstract ( 367 )   PDF (723KB) ( 2039 )   Save At present, the main treatment methods of the patients with advanced colorectal cancer include surgery, chemotherapy, radiotherapy, targeted therapy, physical ablation and immunotherapy, but the chemotherapy is still the main treatment. The emergence of new chemotherapy drugs and the combination of radiotherapy, chemotherapy and targeted therapy in clinical have improved curative effect for the patients with advanced colorectal cancer. In order to better improve the quality of life, reduce side effects and obtain the best effect, now the individual multidisciplinary treatment has become an inevitable trend in the treatment of advanced colorectal cancer in clinical. References | Related Articles | Metrics

Targeted therapy of advanced colorectal cancer Fang Hongyan, Zhou Yunfeng 2016, 43 (5):  391-394.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.019 Abstract ( 408 )   PDF (725KB) ( 1566 )   Save Targeted agents for advanced colorectal cancer mainly include inhibitors of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Studies show that bevacizumab and cetuximab can improve the prognosis of advanced colorectal cancer patients, but there is slight difference in the choice of chemotherapy regimens when combined with them. Bevacizumab and cetuximab can improve the overall survival of Kras wildtype colorectal cancer patients similarly. The emergence of new targeted drugs such as aflibercept, regorafenib provides more choices for the targeted therapy of advanced colorectal cancer patients. References | Related Articles | Metrics

Diagnosis and prognosis evaluation of 18FFDG PET/CT in bone marrow infiltration of lymphoma Yue Jin, Su Liping 2016, 43 (5):  395-397.  doi: 10.3760/cma.j.issn.1673-422X.2016.05.020 Abstract ( 490 )   PDF (722KB) ( 1393 )   Save 18Ffluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) and bone marrow biopsy (BMB) have high consistency in the detection of lymphoma bone marrow infiltration (BMI). 18FFDG PET/CT has a high sensitivity to Hodgkin lymphoma (HL) and aggressive nonHodgkin lymphoma (NHL) BMI, while the sensitivity of indolent NHL is low. Since 18FFDG PET/CT may appears false positive or false negative, so it can not replace the conventional BMB. We can carry out a BMB under the guidance of 18FFDG PET/CT, which can greatly improve the detection rate of BMI. References | Related Articles | Metrics